drugset / Trial / NCT04575259
OLE Study for Patients With Parkinson's Disease With Dementia Enrolled in Study ANAVEX2-73-PDD-001
Phase 2
Completed
132 enrolled
Anavex Life Sciences Corp.
Anavex Australia Pty Ltd. · collabAnavex Germany GmbH · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase 2 open-label extension study to evaluate the effects of ANAVEX2-73 on safety and efficacy of daily treatment.
Timeline
- Start
- 2019-10-10
- Primary completion
- 2022-05-31
- Completion
- 2022-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Blarcamesine | Small molecule | — | Oral |